If this stock drops to 40c it will be soaked up pretty quickly...

If this stock drops to 40c it will be soaked up pretty quickly and wont be staying there for long (or at all if people adjust their stop loss orders and simply put a short on the stock to hedge it if things go bad). The work is largely done as the concept is based on a proven method.

My question: If the FDA says 2 studies are required is it open to IXC to amend their EU study scope to address the gaps/ concerns identified by the FDA and submit those results to the FDA if lieu of a second FDA study? Would the FDA permit a single trial on the condition that EU studies/results hit all milestones/ concerns/ standards required by FDA to justify a single study in the US?

I am a little unfamiliar with the flexibility around the study submission process, so appreciate anyone who can clarify.